Xuanzhu Biopharm nabs $96m and 58 more deal updates worth over $2b

Xuanzhu Biopharmaceutical Co Ltd, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group, has secured over 610.5 million yuan ($96 million) in its Series B round of financing led by Sunshine Insurance Group. 

The latest round brings the company’s market valuation to 7 billion yuan ($1.1 billion). 

Bank of China’s BOCGI, Efung Capital, China Zhongji Investment, TJ Capital, SDIC Taikang Trust and Qianhai FOF joined the round. 

WinX Capital served as the financial advisor for the deal. 

Xuanzhu will use the proceeds for its pipeline candidates and technology innovation, it said. 

Xuanzhu develops drugs targeting therapy areas associated with cancers, metabolic disorders and infectious diseases. 

CHINA DEAL MONITOR

DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on December 27, 2021 – January 04, 2022. 

Expand Table

StartupHeadquarterInvestment Size (USD)Investment StageLead Investor(s)Other Investor(s)Verticals
ZTO Freight Shanghai300 million B--Ridesharing /Transport
Thousand OaksNantong 236 million -Goldstone Capital, CDH Mezzanine and Credit-HealthTech
AntiyHarbin141 million C--Infrastructure
ROBOSENShenzhen100 million B, B+B+: Cedarlake CapitalB: Rencent Capital, Lightspeed China Partners, Sequoia Capital China, Dayone Capital, Gracier Capital; B: Sequoia Capital China, Dayone Capital, Gracier Capital, Enlight Growth Partners, Bohai Capital Robotics & Drones
Parametrix.aiShenzhen100 million BSequoia Capital China5Y Capital, Gaorong Capital AI and Machine Learning
Xuanzhu Biopharm Shijiazhuang 96 million BSunshine Insurance Group Efung Capital, China Zhongji Investment, TJ Capital, SDIC Taikang Trust, Qianhai FOF, BOCGI, Jinjiang Xuanhong Investment, Shanxi Finnancial Holding Group, Wanxin Capital, DNV Capital, HY CapitalHealthTech
GenfleetShanghai79 millionCHuagai Capital Suzhou Suxin Venture Capital, Cherami Capital, ABC International, DYEE Capital, Qiaojing Capital, Baidu Ventures, Wenzhou Investment, CDH Investments, Lake Blue Capital, HM Capital, Panlin Capital, Shanjin Capital HealthTech
Starblaze Technology Beijing 79 millionB1, B2-B1: Qidi New Infrastructure Fund, Zhengqi Holdings, Zhongdian Tuofang; B2: Shanghai Guotou,
Hangzhou Oriental Jiafu Asset Management, SRHC
Internet of Things
Lineprinting MaterialsWuxi64 million A+V-Capital Baoding Investment, Wuxi Huishan Government FundNanotechnology
Hefei Ic Valley MicroelectronicsHefei 63 million CGF Qianhe Costone CapitalN/A
Amador BioscienceHangzhou60 million B+MSA Capital Sequoia Capital China, GL Ventures, Co-win VenturesHealthTech
Kind Pharmaceutical Hangzhou50 million BNorthern Light Venture Capital, Gaorong CapitalDecheng Capital, Ancheng Capital, Efung Capital HealthTech
YeelightQidao47 millionE-Everbright Limited, Huatai Yuanhong, Xindongneng Capital, Qingdao Technology Innovation Fund, Huaying Venture Capital, Yichen Capital N/A
Youibot Shenzhen47 millionBFG Capital, Xicheng Jinrui IDG Capital, Green Pine Capital Partners, SIG, Bluerun Ventures, SoftBank Capital, HAXRobotics & Drones
MoonBiotechGuangzhou31 millionCSDIC Venture Capital -Biotech
SpesHangzhou31 millionAHuaxing Growth Capital SIGBeauty & Hygiene
CytosinLab TherapeuticsShenzhen31 millionA-Zeyue Capital, CDH Investments, Kaitai Capital, Yingnuo Meidi Investment, Hengxu Capital Biotech
ABM Therapeutics Shanghai/San Diego30 million BHighlight Capital, Photon FundLongDAC, Baidu Ventures, Delta Capital,Hermed Capital, Sincere VCHealthTech
ChoiceformShanghai30 million -Sequoia Capital China, Zoo CapitalAlbatross Venture, Aqua VenturesBig Data
LeapstackShanghai24 million CLegend Capital Peakview Capital, GF Qianhe, Huazhi Capital Insuretech
ChipONShanghai* 15 million C1-Shanghai Sailing Capital Management, CICC Capital, Hypercycle Venture, Tianjin Biotechnology Innovation and Incubation Center, Xuanyuan Youyi, Silicon Harbour CapitalN/A
 JJETChengdu* 15 million A-GL VenturesHealthTech
Cardiolink ScienceShenzhen* 15 million DAstraZeneca CICC CapitalCICC Qiyuan Capital HealthTech
Sichain SemiconductorShanghai* 15 million Pre-AGL Ventures-CleanTech
StarBeijing * 15 million B-Legend Capital N/A
WorldExShanghai* 15 million Pre-A, APre-A: Huagai Technology Fund; A: Xinchuangjian Logistics Investment-Ridesharing /Transport
VirtAI TechBeijing * 15 million B+CDB Development FundGL Ventures, Prosperity7 Ventures, Oriza PriorAI and Machine Learning
OMNISuzhou* 15 million DShanghai Biopharmaceutical FundBOCGI, Taikun Capital, Origins Capital, Zhongxin Capital, Zhangke Herun Capital HealthTech
Zhejiang JYSS Bio-EngineeringHangzhou* 15 million B+--HealthTech
Standard RobotsShenzhen* 15 million Pre-CBroad Vision FundsNIO Capital, Source Code Capital, MiracleplusRobotics & Drones
Hangzhou Meichuang TechnologyHangzhou15 million --Weicun Zhike, Shenzhen Guozhong Venture Capital Management, Oriental Fortune Capital Infrastructure
IKASShenzhen15 million BCTC Capital, Nuohua CapitalCR MicroN/A
Cyber KunlunBeijing 15 million -CICC Chuanyu Fenghuang FundHIKE Capital, ZhenFund, Sequoia Capital China Infrastructure
Vision Pharma Shanghai15 million Pre-AZhangjiang Herun, Wenzhou InvestmentRCVHealthTech
MagicalignShanghai15 million Pre-CHPE, 3E Bioventures, Eyebright, Aibo Qingshi -HealthTech
ChengmandianChuzhou13 million Pre-AYingke PE-Electric/Hybrid Vechicles
Shenzhen Lochn Optics TechnologyShenzhen15 million CHuaqiang CapitalEverest VC, Haojun Capital, Guiquan Changqing Investment, Junsheng Capital AR & VR
10kgenomicsShanghai15 million ACD CapitalUnifortune, Northern Light Venture Capital Biotech
TIH MicroelectronicsJinan15 million AGF Qianhe, Chengye Capital Internet of Things
Micro CreativeZhuhai15 million BSummitview Capital Shunwei Capital, Flytouav, Zhuhai Ligao, Suzhou Qingyuan, LiheInfrastructure
iNSSuzhou15 million AOriza Holdings, Oriza FOFs, Oriza JinguQigao Capital AI and Machine Learning
Zhen Health Beijing 15 million B-Hua Xia Heng Tian, Fuhe Yongxin Venture Capital HealthTech
RANetworks Shenzhen15 million CGuangxi Investment GroupYing CapitalInternet of Things
KOSSELSuzhou15 million Ming Bioventures, IN Capital Lingchuang Weilai N/A
Passion Suzhou15 million AYingxinggu Capital Angel Around Robotics & Drones
SpaceShanghai15 million AOriza HuaYunqi PartnersAutonomous Driving
Reunion Shanghai15 million A-Qiming Venture Partners, Taiyu Capital, Deshi Capital HealthTech
TreelabShanghai* 10 million A-Sequoia Capital China, GGV Capital, 5Y Capital, Future Capital Big Data
SphereExBeijing 10 millionPre-AVision Knight CapitalSequoia Capital China, Chuxin Capital, Index Capital Big Data
Leyue Health Beijing * 1.5 million B+CE Innovation Capital, Shenzhen Capital Group, C&R Healthcare FundCowin Capital Insuretech
YuanjingtaikeBeijing * 1.5 million --Yuanbio VentureHealthTech
Pixelcore.aiBeijing * 1.5 million Debut Beijing E-town International Investment&Development China Capital ManagementAI and Machine Learning
FeiyuTechShenzhen* 1.5 million A+-Shanshan Venture Capital Internet of Things
INFI BRAIN TECHBeijing * 1.5 million Pre-A+Legend Star, MSA CapitalLinear Capital, Source Code Capital HealthTech
Yutech Shenzhen* 1.5 million ADelian Capital Shenzhen Credit Guarantee Group, Qingsong Fund, BAIC CapitalN/A
Nolibox Beijing * 1.5 million Pre-A-GL VenturesAI and Machine Learning
netpower.comBeijing * 1.5 million B+-Cornerstone Venture Capital Infrastructure
LinkedCareShanghai-D+-Cowin Capital, Jiawei Gan (Individual Investor)Saas
Chuanxin Biopharmaceuticals Suzhou-Angel+CCB Healthcare Fund, Yuanbio Venture Capital Hongtai AplusBiotech

∗ indicates that the company did not provide the specific size of the deal but only a range. So, we adopt the smallest number in the range – for hundreds of million yuan, the figure is kept at 100 million yuan (or $15 million) and for tens of million yuan, it is 10 million yuan (or $1.5 million). 

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.